Previous Article | Next Article ![]()
Infection and Immunity, September 2000, p. 4986-4991, Vol. 68, No. 9
Department of Immunology, Pasteur Institute,
Paris 15, France,1 and Department of
Molecular Genetics and Biochemistry, University of Pittsburgh School of
Medicine, Pittsburgh, Pennsylvania 152612
Received 24 February 2000/Returned for modification 11 April
2000/Accepted 13 June 2000
A complement regulatory protein (CRP) of Trypanosoma
cruzi was evaluated as a vaccine candidate in a murine model of
experimental T. cruzi infection. Recombinant CRP derived
from an Escherichia coli expression system and a plasmid
encoding the full-length crp structural gene under the
control of a eukaryotic promoter were used to immunize BALB/c mice.
Immunization with both protein and DNA vaccines resulted in a Th1-type
T-cell response, comparable antibody titers, and similar immunoglobulin
G isotype profiles. Only mice immunized with the crp DNA
plasmid produced antibodies capable of lysing the parasites in the
presence of complement and were protected against a lethal challenge
with T. cruzi trypomastigotes. These results demonstrate
the superiority of DNA immunization over protein immunization with the
recombinant CRP. The work also supports the further investigation of
CRP as a component of a multigene, anti-T. cruzi DNA vaccine.
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
DNA-Based Immunization with Trypanosoma
cruzi Complement Regulatory Protein Elicits Complement Lytic
Antibodies and Confers Protection against Trypanosoma
cruzi Infection
*
Corresponding author. Mailing address: Department of
Molecular Genetics and Biochemistry, E1240 Biomedical Science Tower, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261. Phone: (412) 648-8848. Fax: (412) 624-1401. E-mail:
kan1{at}pitt.edu.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|